Mon panier

Sortilin

Sortilin Informations sur la molécule

Nom anglaisSortilinNombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cible100 kDa NT receptor,NT3,Glycoprotein 95,LDLCQ6,NTR3,Gp95,Sortilin 1,Neurotensin receptor 3
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisSortilin
Alias de la cible100 kDa NT receptor,NT3,Glycoprotein 95,LDLCQ6,NTR3,Gp95,Sortilin 1,Neurotensin receptor 3
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

Sortilin Liste de produits

  • Attribut

    Protein (5)Cell (1)

  • Bibliothèque de produits

    En ligne (6)

  • Espèces

    Human (3)Cynomolgus (1)Rat (1)Canine (1)

  • Étiquette

    His Tag (4)His Tag & Avi Tag (1)- (1)

  • Marqueur

    Unconjugated (4)Biotin-labeled (1)- (1)

SortilinContexte de la molécule

The Sortilin is a sorting receptor in the Golgi compartment and as a clearance receptor on the cell surface. Required for protein transport from the Golgi apparatus to the lysosomes by a pathway that is independent of the mannose-6-phosphate receptor (M6PR). Lysosomal proteins bind specifically to the receptor in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex. The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer.

SortilinAlias de la molécule

Sortilin,SORT1,100 kDa NT receptor,Glycoprotein 95,Gp95,Gp95LDLCQ6,Neurotensin receptor 3,NT3NTR3,Ntr3,sortilin 1,

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
VES-001VES001; VES-001Phase 2 ClinicalVesper Bio APSDementia; Frontotemporal Dementia; Frontotemporal Lobar Degeneration
Details
LatozinemabAL-001; GSK-4527223Phase 1 ClinicalAlector Inc, Glaxosmithkline PlcAmyotrophic Lateral Sclerosis; Frontotemporal Dementia; Neurodegenerative Diseases
Details
ARB-1-6ARB-1-6; PQ-203Phase 1 ClinicalProteinQure IncBreast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
  • Liste de produits
  • Informations sur les médicaments cliniques